By Colin Kellaher
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of dollars to Stoke.
The biotechnology companies on Tuesday said they will work together to develop and commercialize zorevunersen outside of North America, with Biogen making an upfront payment of $165 million to Stoke.
As part of the agreement, Cambridge, Mass.-based Biogen will receive exclusive rest-of-world commercialization rights to zorevunersen, while Stoke, based in Bedford, Mass., retains exclusive rights the U.S., Canada and Mexico, the companies said.
Stoke is also eligible for up to $385 million in development and commercial milestone payments, along with royalties on potential sales in Biogen's territory.
The companies said Biogen will also chip in 30% of external clinical development costs for zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome, a genetic disorder characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments.
Stoke is on track to launch a global Phase 3 registrational study of zorevunersen in the second quarter, with a pivotal data readout expected in the second half of 2027 that is expected to support global regulatory filings, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 18, 2025 08:55 ET (13:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。